Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NBI-1117567 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NBI-1117567 Low Dose | EXPERIMENTAL | Participants will receive the titration dose of NBI-1117567 followed by the target dose (low dose) for 10 weeks. |
| NBI-1117567 High Dose | EXPERIMENTAL | Participants will receive the titration dose of NBI-1117567 followed by the target dose (high dose) for 10 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| NBI-1117567 | DRUG | NBI-1117567 will be administered per schedule specified in the arm description. |
| Placebo | DRUG | Placebo matching to NBI-1117567 will be administered per schedule specified in the arm description. |
Key Inclusion Criteria: * Participant has a primary diagnosis of mild to moderate AD prior to screening. * Participant is receiving a well-tolerated treatment with an acetylcholinesterase inhibitor (donepezil, galantamine, or rivastigmine) at a stable dose for at least 3 months prior to the Screeni...
Top 20 of 23 competitors